Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MYC and MET cooperatively drive hepatocellular carcinoma with distinct molecular traits and vulnerabilities
Celia Sequera, Margherita Grattarola, Ágnes Holczbauer, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 11
Open Access | Times Cited: 22

Showing 22 citing articles:

Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making
Renumathy Dhanasekaran, Hiroyuki Suzuki, L Lemaître, et al.
Hepatology (2023)
Closed Access | Times Cited: 25
Multifaceted role of NF-κB in hepatocellular carcinoma therapy: Molecular landscape, therapeutic compounds and nanomaterial approaches
Reena Gupta, Mustafa M. Kadhim, Abduladheem Turki Jalil, et al.
Environmental Research (2023) Vol. 228, pp. 115767-115767
Closed Access | Times Cited: 17
The role of Aurora kinase A in hepatocellular carcinoma: Unveiling the intriguing functions of a key but still underexplored factor in liver cancer
Luca Grisetti, Clarissa Joy C. Garcia, Anna Alessia Saponaro, et al.
Cell Proliferation (2024) Vol. 57, Iss. 8
Open Access | Times Cited: 8
MYC in liver cancer: mechanisms and targeted therapy opportunities
Furong Liu, Zhibin Liao, Zhanguo Zhang
Oncogene (2023) Vol. 42, Iss. 45, pp. 3303-3318
Closed Access | Times Cited: 15
Inhibition of PTPRE suppresses tumor progression and improves sorafenib response in hepatocellular carcinoma
Renshun Dong, Tianci Wang, Wei Dong, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 173, pp. 116366-116366
Open Access | Times Cited: 4
Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?
Wiebke Werner, Maria Kuzminskaya, Isabella Lurje, et al.
Seminars in Liver Disease (2024) Vol. 44, Iss. 02, pp. 159-179
Open Access | Times Cited: 4
In vivo CRISPR activation screening reveals Chromosome 1q genes VPS72, GBA1, and MRPL9 drive hepatocellular carcinoma
Alexandra M. Vázquez-Salgado, Chunmiao Cai, Markcus Lee, et al.
Cellular and Molecular Gastroenterology and Hepatology (2025) Vol. 19, Iss. 5, pp. 101460-101460
Open Access
MET Activation in Lung Cancer and Response to Targeted Therapies
Sarah Anna Okun, Daniel Lu, Katherine Sew, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 281-281
Open Access
SGLT2i delays c-Myc-induced HCC progression via targeting mTOR
Huiling Rao, Xiaotong An, Xiaoyan Qu, et al.
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease (2025), pp. 167805-167805
Closed Access
Comprehensive insights of etiological drivers of hepatocellular carcinoma: Fostering targeted nano delivery to anti-cancer regimes
Dipanjan Ghosh, Aharna Guin, Ashok Kumar, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189318-189318
Closed Access
SPP1 could be an immunological and prognostic biomarker: From pan‐cancer comprehensive analysis to osteosarcoma validation
Zhiming Zhang, Binfeng Liu, Zhengjun Lin, et al.
The FASEB Journal (2024) Vol. 38, Iss. 14
Open Access | Times Cited: 2
Targeted transcriptional downregulation of MYC using epigenomic controllers demonstrates antitumor activity in hepatocellular carcinoma models
William Senapedis, Kayleigh Gallagher, Elmer Figueroa, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
Multiple Roles of LOXL2 in the Progression of Hepatocellular Carcinoma and Its Potential for Therapeutic Targeting
Jelena Radić, Bojana Kožik, Ivan Nikolić, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11745-11745
Open Access | Times Cited: 5
Recent developments in molecular targeted therapies for hepatocellular carcinoma in the genomic era
Ugo Testa
Expert Review of Molecular Diagnostics (2024) Vol. 24, Iss. 9, pp. 803-827
Open Access
Comprehensive analysis of the RBP regulome reveals functional modules and drug candidates in liver cancer
Mateusz Garbulowski, Riccardo Mosca, Carlos J. Gallardo-Dodd, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Single cell landscape of potential mechanisms in primary and metastatic hepatocellular carcinoma
Shibo Zhang, Yi Li, Mingxing Chu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Risk prediction for dermatomyositis-associated hepatocellular carcinoma
Xusheng Zhang, Yongxin Ma, Kejun Liu, et al.
BMC Bioinformatics (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Risk prediction for Dermatomyositis-associated hepatocellular carcinoma
Xusheng Zhang, Yongxin Ma, Kejun Liu, et al.
Research Square (Research Square) (2023)
Open Access
Additional file 1 of Risk prediction for dermatomyositis-associated hepatocellular carcinoma
Xusheng Zhang, Yongxin Ma, Kejun Liu, et al.
Figshare (2023)
Open Access
Additional file 3 of Risk prediction for dermatomyositis-associated hepatocellular carcinoma
Xusheng Zhang, Yongxin Ma, Kejun Liu, et al.
Figshare (2023)
Open Access
Additional file 4 of Risk prediction for dermatomyositis-associated hepatocellular carcinoma
Xusheng Zhang, Yongxin Ma, Kejun Liu, et al.
Figshare (2023)
Open Access
Additional file 2 of Risk prediction for dermatomyositis-associated hepatocellular carcinoma
Xusheng Zhang, Yongxin Ma, Kejun Liu, et al.
Figshare (2023)
Open Access
Page 1

Scroll to top